Limited Use — Reason for Use code 265, 266, 267, 268 requiredMarketed · checked 2026-09-18
StatusLimited Use — Reason for Use code 265, 266, 267, 268 required
Write on scriptLU code 265, 266, 267, 268 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Salbutamol · DIN 02208229
Manufacturer: Pharmascience Inc.; listing date 1997-04-10
Health Canada: Marketed since 2010-05-07 · brand PMS-SALBUTAMOL · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 1 MG/ML · company Pharmascience inc · schedule Prescription
PMS-Salbutamol: Formulary list price $0.3617/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3617 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19763 · Verify on the e-Formulary ↗ (DIN 02208229)
Source record
DIN 02208229: PMS-Salbutamol
Raw flags: sec12=Y, sec3=Y
Item: 121200048; group id 232; item number 0412; lccId 00040; manufacturer id PMS
Source form: Inh Sol- 2.5mL Pk; strength: 1mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3617; ministry $0.3617
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02208229
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19763Interchangeable products
Teva-Salbutamol Sterinebs P.F. · DIN 01926934 · $0.3617
Ventolin Nebules P.F. · DIN 02213419 · not recorded
Shortage status: resolved shortage (ended 2025-03-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02208229
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Salbutamol Sterinebs P.F. · DIN 01926934 · 1mg/mL · Inh Sol- 2.5mL Pk
Limited Use — Reason for Use code 265, 266, 267, 268 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 265, 266, 267, 268 required
Write on scriptLU code 265, 266, 267, 268 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Salbutamol Sterinebs P.F. · DIN 01926934
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Health Canada: Marketed since 2012-07-06 · brand TEVA-SALBUTAMOL STERINEBS P.F. · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 1 MG/ML · company Teva canada limited · schedule Prescription
Teva-Salbutamol Sterinebs P.F.: Formulary list price $0.3617/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3617 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13550 · Verify on the e-Formulary ↗ (DIN 01926934)
Source record
DIN 01926934: Teva-Salbutamol Sterinebs P.F.
Raw flags: sec12=Y, sec3=Y
Item: 121200048; group id 232; item number 0412; lccId 00040; manufacturer id TEV
Source form: Inh Sol- 2.5mL Pk; strength: 1mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3617; ministry $0.3617
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01926934
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13550Interchangeable products
PMS-Salbutamol · DIN 02208229 · $0.3617
Ventolin Nebules P.F. · DIN 02213419 · not recorded
Shortage status: resolved shortage (ended 2025-11-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01926934
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Limited Use — Reason for Use code 265, 266, 267, 268 requiredMarketed · checked 2026-09-18
StatusLimited Use — Reason for Use code 265, 266, 267, 268 required
Write on scriptLU code 265, 266, 267, 268 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Salbutamol · DIN 02208237
Manufacturer: Pharmascience Inc.; listing date 1997-04-10
Health Canada: Marketed since 2010-05-07 · brand PMS-SALBUTAMOL · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 2 MG/ML · company Pharmascience inc · schedule Prescription
PMS-Salbutamol: Formulary list price $0.6750/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6750 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19762 · Verify on the e-Formulary ↗ (DIN 02208237)
Source record
DIN 02208237: PMS-Salbutamol
Raw flags: sec12=Y, sec3=Y
Item: 121200070; group id 233; item number 0413; lccId 00041; manufacturer id PMS
Source form: Inh Sol- 2.5mL Pk; strength: 2mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6750; ministry $0.6750
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02208237
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19762Interchangeable products
Teva-Salbutamol Sterinebs P.F. · DIN 02173360 · $0.6750
Ventolin Nebules P.F. · DIN 02213427 · not recorded
Shortage status: resolved shortage (ended 2025-11-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02208237
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Salbutamol Sterinebs P.F. · DIN 02173360 · 2mg/mL · Inh Sol- 2.5mL Pk
Limited Use — Reason for Use code 265, 266, 267, 268 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 265, 266, 267, 268 required
Write on scriptLU code 265, 266, 267, 268 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Salbutamol Sterinebs P.F. · DIN 02173360
Manufacturer: Teva Canada Limited; listing date 1997-04-10
Health Canada: Marketed since 2012-07-05 · brand TEVA-SALBUTAMOL STERINEBS P.F. · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 2 MG/ML · company Teva canada limited · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19058 · Verify on the e-Formulary ↗ (DIN 02173360)
Source record
DIN 02173360: Teva-Salbutamol Sterinebs P.F.
Raw flags: sec12=Y, sec3=Y
Item: 121200070; group id 233; item number 0413; lccId 00041; manufacturer id TEV
Source form: Inh Sol- 2.5mL Pk; strength: 2mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6871; ministry $0.6750
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02173360
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19058Interchangeable products
PMS-Salbutamol · DIN 02208237 · $0.6750
Ventolin Nebules P.F. · DIN 02213427 · not recorded
Shortage status: resolved shortage (ended 2025-06-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02173360
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ventolin · DIN 02213486 · 5mg/mL · Inh Sol-10mL Pk
Limited Use — Reason for Use code 256, 257, 258, 259 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 256, 257, 258, 259 required
Write on scriptLU code 256, 257, 258, 259 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 256, 257, 258, 259
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 256
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 257
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 258
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 259
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Ventolin · DIN 02213486
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1998-04-03
Health Canada: Marketed since 2002-08-26 · brand VENTOLIN RESPIRATOR SOLUTION · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 5 MG/ML · company Glaxosmithkline inc · schedule Prescription
Ventolin: Formulary list price $3.1700/unit (unit not stated in source; not the patient's cost)
Ministry pays: $3.1700 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43108 · Verify on the e-Formulary ↗ (DIN 02213486)
Source record
DIN 02213486: Ventolin
Raw flags: sec12=Y, sec3=Y
Item: 121200025; group id 234; item number 0414; lccId 00042; manufacturer id GSK
Source form: Inh Sol-10mL Pk; strength: 5mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.1700; ministry $3.1700
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02213486
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43108
Shortage status: resolved shortage (ended 2024-10-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213486
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Salbutamol HFA · DIN 02245669
Manufacturer: Apotex Inc.; listing date 2003-01-01
Health Canada: Marketed since 2019-12-16 · brand APO-SALBUTAMOL HFA · ATC R03AC02 SALBUTAMOL · form Aerosol (metered-dose) · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 100 MCG/ACT · company Apotex inc · schedule Prescription
Apo-Salbutamol HFA: Formulary list price $5.0000/unit (unit not stated in source; not the patient's cost)
Ministry pays: $5.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69769 · Verify on the e-Formulary ↗ (DIN 02245669)
Source record
DIN 02245669: Apo-Salbutamol HFA
Raw flags: sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id APX
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $5.0000; ministry $5.0000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245669
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69769Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000
Apo-Salvent · DIN 00790419 · not recorded
Novo-Salbutamol HFA · DIN 02326450 · $5.0000
Novo-Salmol · DIN 00874086 · not recorded
Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded
Salbutamol HFA · DIN 02419858 · $5.0000
Ventolin · DIN 02213478 · not recorded
Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: active shortage (reported 2026-06-16, last updated 2026-06-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245669
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Novo-Salbutamol HFA · DIN 02326450
Manufacturer: Novopharm Ltd.; listing date 2011-05-19
Health Canada: Marketed since 2018-03-21 · brand TEVA-SALBUTAMOL HFA · ATC R03AC02 SALBUTAMOL · form Aerosol (metered-dose) · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 100 MCG/ACT · company Teva canada limited · schedule Prescription
Novo-Salbutamol HFA: Formulary list price $5.0000/unit (unit not stated in source; not the patient's cost)
Ministry pays: $5.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81180 · Verify on the e-Formulary ↗ (DIN 02326450)
Source record
DIN 02326450: Novo-Salbutamol HFA
Raw flags: sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id NOP
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $5.0000; ministry $5.0000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02326450
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81180Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000
Apo-Salbutamol HFA · DIN 02245669 · $5.0000
Apo-Salvent · DIN 00790419 · not recorded
Novo-Salmol · DIN 00874086 · not recorded
Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded
Salbutamol HFA · DIN 02419858 · $5.0000
Ventolin · DIN 02213478 · not recorded
Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: resolved shortage (ended 2025-03-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02326450
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Salbutamol HFA · DIN 02419858
Manufacturer: Sanis Health Inc.; listing date 2020-04-07
Health Canada: Marketed since 2014-02-13 · brand SALBUTAMOL HFA · ATC R03AC02 SALBUTAMOL · form Aerosol (metered-dose) · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 100 MCG/ACT · company Sanis health inc · schedule Prescription
Salbutamol HFA: Formulary list price $5.0000/unit (unit not stated in source; not the patient's cost)
Ministry pays: $5.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90447 · Verify on the e-Formulary ↗ (DIN 02419858)
Source record
DIN 02419858: Salbutamol HFA
Raw flags: sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id SAI
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $5.0000; ministry $5.0000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02419858
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90447Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000
Apo-Salbutamol HFA · DIN 02245669 · $5.0000
Apo-Salvent · DIN 00790419 · not recorded
Novo-Salbutamol HFA · DIN 02326450 · $5.0000
Novo-Salmol · DIN 00874086 · not recorded
Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded
Ventolin · DIN 02213478 · not recorded
Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: resolved shortage (ended 2026-03-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02419858
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ventolin HFA · DIN 02241497
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2009-11-13
Health Canada: Marketed since 2001-11-22 · brand VENTOLIN HFA · ATC R03AC02 SALBUTAMOL · form Aerosol (metered-dose) · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 100 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65137 · Verify on the e-Formulary ↗ (DIN 02241497)
Source record
DIN 02241497: Ventolin HFA
Raw flags: sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id GSK
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $6.0000; ministry $5.0000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241497
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65137Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000
Apo-Salbutamol HFA · DIN 02245669 · $5.0000
Apo-Salvent · DIN 00790419 · not recorded
Novo-Salbutamol HFA · DIN 02326450 · $5.0000
Novo-Salmol · DIN 00874086 · not recorded
Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded
Salbutamol HFA · DIN 02419858 · $5.0000
Ventolin · DIN 02213478 · not recorded
Shortage status: resolved shortage (ended 2025-04-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02241497
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Airomir HFA · DIN 02232570
Manufacturer: Graceway Pharmaceuticals; listing date 1998-12-31
Health Canada: Dormant since 2025-07-30 · brand AIROMIR · ATC R03AC02 SALBUTAMOL · form Aerosol (metered-dose) · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 100 MCG/ACT · company Bausch health, canada inc. · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=52048 · Verify on the e-Formulary ↗ (DIN 02232570)
Source record
DIN 02232570: Airomir HFA
Raw flags: sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id GRA
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $6.2593; ministry $5.0000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02232570
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=52048Interchangeable products
Apo-Salbutamol HFA · DIN 02245669 · $5.0000
Apo-Salvent · DIN 00790419 · not recorded
Novo-Salbutamol HFA · DIN 02326450 · $5.0000
Novo-Salmol · DIN 00874086 · not recorded
Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded
Salbutamol HFA · DIN 02419858 · $5.0000
Ventolin · DIN 02213478 · not recorded
Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: discontinued (2023-01-04, reported by BAUSCH HEALTH, CANADA INC.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02232570
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-07-30 — choose a marketed DIN from the same-category list.
Ventolin · PIN 01961039 · 2mg · tablet
Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ventolin · DIN 01961039
Manufacturer: Glaxo Canada Inc.; listing date 1996-10-01
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 01961039: Ventolin
Raw flags: notABenefit=Y, sec3=Y
Item: 121200013; group id 235; item number 0416; lccId None; manufacturer id GLA
Source form: Tab; strength: 2mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01961039
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Apo-Salvent · DIN 02146843 · $0.1274
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01961039
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Salvent · DIN 02146843 · 2mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2018-12-20 — choose a marketed DIN from the same-category list.Discontinued 2018-12-20 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-12-20 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-12-20 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Salvent · DIN 02146843
Manufacturer: Apotex Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2018-12-20 · brand APO-SALVENT TABLETS - 2MG · ATC R03CC02 SALBUTAMOL · form Tablet · route Oral · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 2 MG · company Apotex inc · schedule Prescription
Apo-Salvent: Formulary list price $0.1274/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1274 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18068 · Verify on the e-Formulary ↗ (DIN 02146843)
Source record
DIN 02146843: Apo-Salvent
Raw flags: sec3=Y
Item: 121200013; group id 235; item number 0416; lccId None; manufacturer id APX
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $0.1274; ministry $0.1274
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02146843
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18068Interchangeable products
Ventolin · DIN 01961039 · not recorded
Shortage status: discontinued (2018-07-12, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02146843
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-12-20 — choose a marketed DIN from the same-category list.
Apo-Salvent · DIN 02146851 · 4mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2018-07-12 — choose a marketed DIN from the same-category list.Discontinued 2018-07-12 · checked 2026-09-19
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-07-12 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-07-12 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Salvent · DIN 02146851
Manufacturer: Apotex Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2018-07-12 · brand APO-SALVENT TABLETS - 4MG · ATC R03CC02 SALBUTAMOL · form Tablet · route Oral · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 4 MG · company Apotex inc · schedule Prescription
Apo-Salvent: Formulary list price $0.2134/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2134 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18067 · Verify on the e-Formulary ↗ (DIN 02146851)
Source record
DIN 02146851: Apo-Salvent
Raw flags: sec3=Y
Item: 121200021; group id 235; item number 0417; lccId None; manufacturer id APX
Source form: Tab; strength: 4mg
Recorded listing: General benefit
Source prices (unrounded): $0.2134; ministry $0.2134
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02146851
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18067Interchangeable products
Ventolin · DIN 01932691 · not recorded
Shortage status: discontinued (2018-07-12, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02146851
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-07-12 — choose a marketed DIN from the same-category list.
Ventolin Nebules P.F. · DIN 02213419 · 1mg/mL · Inh Sol- 2.5mL Pk
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.Discontinued 2022-07-05 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Ventolin Nebules P.F. · DIN 02213419
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1998-10-21
Health Canada: Cancelled post market since 2022-07-05 · brand VENTOLIN NEBULES P.F. - 2.5MG/2.5ML · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Glaxosmithkline inc · schedule Prescription
Ventolin Nebules P.F.: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43100 · Verify on the e-Formulary ↗ (DIN 02213419)
Source record
DIN 02213419: Ventolin Nebules P.F.
Raw flags: notABenefit=Y, sec3=Y
Item: 121200048; group id 232; item number 0412; lccId 00040; manufacturer id GSK
Source form: Inh Sol- 2.5mL Pk; strength: 1mg/mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02213419
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43100Interchangeable products
PMS-Salbutamol · DIN 02208229 · $0.3617
Teva-Salbutamol Sterinebs P.F. · DIN 01926934 · $0.3617
Shortage status: discontinued (2022-06-17, reported by GLAXOSMITHKLINE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213419
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.
Ventolin Nebules P.F. · DIN 02213427 · 2mg/mL · Inh Sol- 2.5mL Pk
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.Discontinued 2022-07-05 · checked 2026-09-18
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ventolin Nebules P.F. · DIN 02213427
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2006-06-15
Health Canada: Cancelled post market since 2022-07-05 · brand VENTOLIN NEBULES P.F. - 5MG/2.5ML · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 5 MG/2.5ML · company Glaxosmithkline inc · schedule Prescription
Ventolin Nebules P.F.: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43101 · Verify on the e-Formulary ↗ (DIN 02213427)
Source record
DIN 02213427: Ventolin Nebules P.F.
Raw flags: notABenefit=Y, sec3=Y
Item: 121200070; group id 233; item number 0413; lccId 00041; manufacturer id GSK
Source form: Inh Sol- 2.5mL Pk; strength: 2mg/mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02213427
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43101Interchangeable products
PMS-Salbutamol · DIN 02208237 · $0.6750
Teva-Salbutamol Sterinebs P.F. · DIN 02173360 · $0.6750
Shortage status: discontinued (2022-06-29, reported by GLAXOSMITHKLINE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213427
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.
Ventolin · DIN 01932691 · 4mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.Discontinued 1996-09-10 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ventolin · DIN 01932691
Manufacturer: Glaxo Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 1996-09-10 · brand VENTOLIN TAB 4MG · ATC R03CC02 SALBUTAMOL · form Tablet · route Oral · ingredients SALBUTAMOL SULFATE 4 MG/TAB · company Glaxo canada inc · schedule Prescription
Ventolin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15121 · Verify on the e-Formulary ↗ (DIN 01932691)
Source record
DIN 01932691: Ventolin
Raw flags: notABenefit=Y, sec3=Y
Item: 121200021; group id 235; item number 0417; lccId None; manufacturer id GLA
Source form: Tab; strength: 4mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01932691
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15121Interchangeable products
Apo-Salvent · DIN 02146851 · $0.2134
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01932691
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.Discontinued 2025-04-17 · checked 2026-09-18
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Salvent · DIN 00790419
Manufacturer: Apotex Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2025-04-17 · brand APO-SALVENT AEM 100MCG · ATC R03AC02 SALBUTAMOL · form Metered-dose aerosol · route Inhalation · ingredients SALBUTAMOL 100 MCG/ACT · company Abbott laboratories · schedule Prescription
Apo-Salvent: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9941 · Verify on the e-Formulary ↗ (DIN 00790419)
Source record
DIN 00790419: Apo-Salvent
Raw flags: notABenefit=Y, sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id APX
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00790419
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9941Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000
Apo-Salbutamol HFA · DIN 02245669 · $5.0000
Novo-Salbutamol HFA · DIN 02326450 · $5.0000
Novo-Salmol · DIN 00874086 · not recorded
Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded
Salbutamol HFA · DIN 02419858 · $5.0000
Ventolin · DIN 02213478 · not recorded
Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: active shortage (reported 2017-03-10, last updated 2017-10-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00790419
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-10 — choose a marketed DIN from the same-category list.Discontinued 2005-08-10 · checked 2026-09-18
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2005-08-10 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Novo-Salmol · DIN 00874086
Manufacturer: Novopharm Ltd.; listing date 1996-10-01
Health Canada: Cancelled post market since 2005-08-10 · brand NOVO-SALMOL INHALER 100MCG/AEM · ATC R03CC02 SALBUTAMOL · form Metered-dose aerosol · route Oral · ingredients SALBUTAMOL 100 MCG/ACT · company Novopharm limited · schedule Prescription
Novo-Salmol: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11290 · Verify on the e-Formulary ↗ (DIN 00874086)
Source record
DIN 00874086: Novo-Salmol
Raw flags: notABenefit=Y, sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id NOP
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00874086
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11290Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000
Apo-Salbutamol HFA · DIN 02245669 · $5.0000
Apo-Salvent · DIN 00790419 · not recorded
Novo-Salbutamol HFA · DIN 02326450 · $5.0000
Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded
Salbutamol HFA · DIN 02419858 · $5.0000
Ventolin · DIN 02213478 · not recorded
Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00874086
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2005-08-10 — choose a marketed DIN from the same-category list.
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-07-17 — choose a marketed DIN from the same-category list.Discontinued 2009-07-17 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-07-17 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2009-07-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ratio-Salbutamol Inhaler · DIN 00851841
Manufacturer: Ratiopharm Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2009-07-17 · brand RATIO-SALBUTAMOL · ATC R03AC02 SALBUTAMOL · form Metered-dose aerosol · route Inhalation · ingredients SALBUTAMOL 100 MCG/ACT · company Ratiopharm inc division of teva canada limited · schedule Prescription
Ratio-Salbutamol Inhaler: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10209 · Verify on the e-Formulary ↗ (DIN 00851841)
Source record
DIN 00851841: Ratio-Salbutamol Inhaler
Raw flags: notABenefit=Y, sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id RPH
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00851841
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10209Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000
Apo-Salbutamol HFA · DIN 02245669 · $5.0000
Apo-Salvent · DIN 00790419 · not recorded
Novo-Salbutamol HFA · DIN 02326450 · $5.0000
Novo-Salmol · DIN 00874086 · not recorded
Salbutamol HFA · DIN 02419858 · $5.0000
Ventolin · DIN 02213478 · not recorded
Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00851841
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2009-07-17 — choose a marketed DIN from the same-category list.
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-01-22 — choose a marketed DIN from the same-category list.Discontinued 2003-01-22 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-01-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-01-22 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ventolin · DIN 02213478
Manufacturer: Glaxo Wellcome Inc.; listing date 1997-07-12
Health Canada: Cancelled post market since 2003-01-22 · brand VENTOLIN INHALER · ATC R03AC02 SALBUTAMOL · form Metered-dose aerosol · route Inhalation · ingredients SALBUTAMOL 100 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Ventolin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43105 · Verify on the e-Formulary ↗ (DIN 02213478)
Source record
DIN 02213478: Ventolin
Raw flags: notABenefit=Y, sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id GLW
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02213478
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43105Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000
Apo-Salbutamol HFA · DIN 02245669 · $5.0000
Apo-Salvent · DIN 00790419 · not recorded
Novo-Salbutamol HFA · DIN 02326450 · $5.0000
Novo-Salmol · DIN 00874086 · not recorded
Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded
Salbutamol HFA · DIN 02419858 · $5.0000
Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213478
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2003-01-22 — choose a marketed DIN from the same-category list.
IPRATROPIUM BROMIDE/SALBUTAMOL
2 Limited Use · 1 not a benefit
Other products in the same Health Canada class (R03AC, R03C) — coverage varies; not interchangeable
Terbutaline (Bricanyl Turbuhaler): general benefit
Formoterol (Foradil): limited Use 132
Formoterol (Oxeze Turbuhaler): limited Use 132
Indacaterol (Onbrez Breezhaler): limited Use 443
Salmeterol (SereVent Diskus): limited Use 132, 391
Orciprenaline (Alupent): general benefit, Not a benefit
10 more in the class list below
Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 · 500mcg/2.5mg/2.5mL · Inh Sol-2.5mL Amp Pk
Limited Use — Reason for Use code 256, 257, 258, 259 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 256, 257, 258, 259 required
Write on scriptLU code 256, 257, 258, 259 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 256, 257, 258, 259
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 256
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 257
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 258
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 259
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Ipratropium Bromide and Salbutamol Sulph · DIN 02483394
Manufacturer: MDA Inc.; listing date 2019-12-20
Health Canada: Marketed since 2026-08-28 · brand IPRATROPIUM BROMIDE AND SALBUTAMOL SULPHATE INHALATION SOLUTION · ATC R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 0.5 MG/2.5ML, SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Juno pharma canada inc. · schedule Prescription
Ipratropium Bromide and Salbutamol Sulph: Formulary list price $0.8066/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.8066 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97384 · Verify on the e-Formulary ↗ (DIN 02483394)
Source record
DIN 02483394: Ipratropium Bromide and Salbutamol Sulph
Raw flags: sec12=Y, sec3=Y
Item: 120800050; group id 208; item number 0378; lccId 00029; manufacturer id MDI
Source form: Inh Sol-2.5mL Amp Pk; strength: 500mcg/2.5mg/2.5mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.8066; ministry $0.8066
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02483394
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97384Interchangeable products
Combivent UDV · DIN 02231675 · not recorded
Teva-Combo Sterinebs · DIN 02272695 · $0.8066
Shortage status: resolved shortage (ended 2025-04-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02483394
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Limited Use — Reason for Use code 256, 257, 258, 259 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 256, 257, 258, 259 required
Write on scriptLU code 256, 257, 258, 259 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 256, 257, 258, 259
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 256
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 257
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 258
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 259
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Combo Sterinebs · DIN 02272695
Manufacturer: Teva Canada Limited; listing date 2006-01-24
Health Canada: Marketed since 2012-07-17 · brand TEVA-COMBO STERINEBS · ATC R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE, R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML, IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 0.5 MG/2.5ML · company Teva canada limited · schedule Prescription
Teva-Combo Sterinebs: Formulary list price $0.8066/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.8066 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75820 · Verify on the e-Formulary ↗ (DIN 02272695)
Source record
DIN 02272695: Teva-Combo Sterinebs
Raw flags: sec12=Y, sec3=Y
Item: 120800050; group id 208; item number 0378; lccId 00029; manufacturer id TEV
Source form: Inh Sol-2.5mL Amp Pk; strength: 500mcg/2.5mg/2.5mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.8066; ministry $0.8066
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02272695
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75820Interchangeable products
Combivent UDV · DIN 02231675 · not recorded
Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 · $0.8066
Shortage status: resolved shortage (ended 2025-04-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02272695
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-01-08 — choose a marketed DIN from the same-category list.Discontinued 2020-01-08 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-01-08 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-01-08 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 256, 257, 258, 259
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 256
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 257
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 258
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 259
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Combivent UDV · DIN 02231675
Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 1998-12-31
Health Canada: Cancelled post market since 2020-01-08 · brand COMBIVENT UDV · ATC R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE, R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE, R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 0.5 MG/2.5ML, SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Combivent UDV: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51050 · Verify on the e-Formulary ↗ (DIN 02231675)
Source record
DIN 02231675: Combivent UDV
Raw flags: notABenefit=Y, sec3=Y
Item: 120800050; group id 208; item number 0378; lccId 00029; manufacturer id BOE
Source form: Inh Sol-2.5mL Amp Pk; strength: 500mcg/2.5mg/2.5mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02231675
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51050Interchangeable products
Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 · $0.8066
Teva-Combo Sterinebs · DIN 02272695 · $0.8066
Shortage status: discontinued (2020-01-08, reported by BOEHRINGER INGELHEIM (CANADA) LTD LTEE); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02231675
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2020-01-08 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (12:08 Parasympatholytic (Cholinergic Blocking) Agents) and how they are covered
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: ACLIDINIUM BROMIDE, BENZTROPINE MESYLATE, ETHOPROPAZINE HCL, GLYCOPYRRONIUM BROMIDE, PROCYCLIDINE HCL, TIOTROPIUM BROMIDE MONOHYDRATE, UMECLIDINIUM
Some products covered without a code (check the product listing): IPRATROPIUM BROMIDE, OXYBUTYNIN CHLORIDE, TRIHEXYPHENIDYL HCL
12:08 Parasympatholytic (Cholinergic Blocking) Agents
· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:08
and 5 more
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: EPINEPHRINE HCL, TERBUTALINE SULFATE
Some products covered without a code (check the product listing): ORCIPRENALINE SULFATE
12:12 Sympathomimetic (Adrenergic) Agents
INDICATIONS AND CLINICAL USE
TEVA-SALBUTAMOL STERINEBSTM P.F. (salbutamol sulphate Solution) is indicated for:
• the treatment of severe bronchospasm associated with exacerbations of chronic bronchitis
and bronchial asthma. It can be used by “wet” nebulization. When administered through a
nebulizer, it should be used with compressed air or oxygen.
Pediatrics (< 5 years of age):
Experience is insufficient for recommending the treatment of children under 5 years of age.
https://pdf.hres.ca/dpd_pm/00084629.PDF
PM date: October 28, 2022
Source product: TEVA-SALBUTAMOL STERINEBS P.F.; DIN 01926934; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE
TEVA-COMBO Sterinebs® (salbutamol sulphate and ipratropium bromide) Inhalation
Solution in unit dose vials is indicated for the management of bronchospasm in
patients suffering from chronic obstructive pulmonary disease (COPD) who require
regular treatment with both ipratropium and salbutamol.
Treatment should be initiated and administered under medical supervision, e.g.
in the hospital setting. Home based treatment can be recommended in exceptional
cases (severe symptoms or experienced patients requiring higher doses) when a
low dose rapid acting beta-agonist bronchodilator has been insufficient in
providing relief after consultation with an experienced physician.
Administration should be stopped when sufficient symptom relief is achieved.
Pediatrics:
The efficacy and safety in children and adolescents under 18 years has not been
established. TEVA-COMBO Sterinebs® (salbutamol sulphate and ipratropium bromide)
Inhalation Solution is not indicated in this patient population.
Geriatrics:
Page 3 of 48
Elderly patients can use TEVA-COMBO Sterinebs® (s…
https://pdf.hres.ca/dpd_pm/00033894.PDF
PM date: March 1, 2016
Source product: TEVA-COMBO STERINEBS; DIN 02272695; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Apo-Salbutamol HFA · DIN 02245669
Shortage status: active shortage (reported 2026-06-16, last updated 2026-06-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245669
Ventolin Nebules P.F. · DIN 02213419
Shortage status: discontinued (2022-06-17, reported by GLAXOSMITHKLINE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213419
Ventolin Nebules P.F. · DIN 02213427
Shortage status: discontinued (2022-06-29, reported by GLAXOSMITHKLINE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213427
Apo-Salvent · DIN 00790419
Shortage status: active shortage (reported 2017-03-10, last updated 2017-10-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00790419
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)
Other review policies
For Ventolin, Ventolin Nebules P.F., Apo-Salvent, Novo-Salmol, Ratio-Salbutamol Inhaler, Combivent UDV: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.